Login to Your Account



EULAR Roundup


Thursday, June 7, 2012
• Bristol-Myers Squibb Co., of New York, said the AMPLE (Abatacept Versus Adalimumab Comparison in Biologic-Naïve rheumatoid arthritis Subjects With Background Methotrexate) study met its primary endpoint, as measured by noninferiority, and demonstrated that Orencia (abatacept) plus methotrexate achieved comparable rates of efficacy to Humiara (adalimumab, Abbott) for the American College of Rheumatology criteria of 20 percent response at one year (63.4 percent vs. 64.8 percent).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription